Compliant v. Compatible: Understanding FDA 21 CFR Part 11

It’s not always easy to figure out whether your software is 21 CFR Part 11 compliant or compatible. Regulations for 21 CFR Part 11 state that electronic records, electronic signatures, and handwritten signatures converted into digital copies are all trustworthy, reliable, and equal to handwritten signatures on paper.

Expanding Your Assay Specificity: Cisbio Joins PerkinElmer

Over the last 20 years, Cisbio has become a leading Life Sciences company which develops, manufactures, and markets high quality kits and reagents for the drug discovery and life science markets used by pharmaceutical, biotechnology, academia and contract research organizations across the globe.

Eureka Moment In Nanoecotoxicology

The nanotech world just witnessed a revolution. For the first time in history, scientists at the University of South Carolina’s Center for Environmental NanoScience and Risk (CENR) and PerkinElmer have precisely quantified the uptake of metal nanoparticles by individual cells.

Unraveling The Mysteries Of The Human Microbiome

Researchers have developed an optimized and validated routine method for collecting stool samples to extract DNA for the first time. The method uses PerkinElmer's chemagic MSM I extraction instrument and is expected to accelerate microbiome research.

Innovators in Cancer Immunology: Ovarian Cancer

Cancer researchers are uncovering new insights using our Phenoptics™ Quantitative Pathology Research Solutions. In an ovarian cancer case study, Dr. Feldman uses this instrumentation to modernize pathology.

Innovators in Cancer Immunology: Lymphoma

Cancer researchers are uncovering new insights using our Phenoptics™ Quantitative Pathology Research Solutions. In a lymphoma cancer case study, Dr. Rodig uses the instrumentation to gain insight into tumor pathogenesis.

Innovators in Cancer Immunology: Colorectal Cancer

Cancer researchers are uncovering new insights using our Phenoptics™ Quantitative Pathology Research Solutions. In a colorectal case study, Dr. Galon uses this instrumentation to uncover more details about cancer and the immune system.

Innovators in Cancer Immunology: Breast Cancer

Cancer researchers are uncovering new insights using our Phenoptics™ Quantitative Pathology Research Solutions. In a breast cancer case study, Dr. Rimm uses this instrumentation in her immune-oncology research.

Innovators in Cancer Immunology: Melanoma

Cancer researchers now can visualize more of a tumor than ever before using PerkinElmer’s Phenoptics Quantitative Pathology Research Solutions. In a melanoma case study, Dr. Tumeh uses this instrumentation to develop biomarkers in his cancer immunology research.

Novel Approach to Understanding Dementia

Using a suite of PerkinElmer's analytical imaging instruments, Dementias Platform United Kingdom (DPUK) is taking a whole-body approach to early detection, better treatment, and prevention of neurodegenerative conditions including Parkinson’s Disease, Motor Neurone Diseases, Multiple Sclerosis, Huntington’s Disease, Creutzfeldt–Jakob Disease, and Alzheimer’s Disease.

More Stories